AR066587A1 - DOSAGE FORM INCLUDING 10 - [(3S)) - 1-AZABICICLO [2.2.2] OCT-3 -ILMETIL] -10H-PHENOTIAZINE PROVIDED IN ADEQUATE FORM FOR ORAL ADMINISTRATION OF A DAILY DOSE OF 1 MG TO 3 MG - Google Patents
DOSAGE FORM INCLUDING 10 - [(3S)) - 1-AZABICICLO [2.2.2] OCT-3 -ILMETIL] -10H-PHENOTIAZINE PROVIDED IN ADEQUATE FORM FOR ORAL ADMINISTRATION OF A DAILY DOSE OF 1 MG TO 3 MGInfo
- Publication number
- AR066587A1 AR066587A1 ARP080102067A ARP080102067A AR066587A1 AR 066587 A1 AR066587 A1 AR 066587A1 AR P080102067 A ARP080102067 A AR P080102067A AR P080102067 A ARP080102067 A AR P080102067A AR 066587 A1 AR066587 A1 AR 066587A1
- Authority
- AR
- Argentina
- Prior art keywords
- oct
- oral administration
- daily dose
- dosage form
- azabiciclo
- Prior art date
Links
- 239000002552 dosage form Substances 0.000 title abstract 3
- HOKDBMAJZXIPGC-INIZCTEOSA-N 10-[[(3s)-1-azabicyclo[2.2.2]octan-3-yl]methyl]phenothiazine Chemical compound C12=CC=CC=C2SC2=CC=CC=C2N1C[C@H]1C(CC2)CCN2C1 HOKDBMAJZXIPGC-INIZCTEOSA-N 0.000 abstract 2
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 abstract 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 abstract 1
- 108010003541 Platelet Activating Factor Proteins 0.000 abstract 1
- 206010039085 Rhinitis allergic Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000000172 allergic effect Effects 0.000 abstract 1
- 201000010105 allergic rhinitis Diseases 0.000 abstract 1
- 229940121363 anti-inflammatory agent Drugs 0.000 abstract 1
- 239000002260 anti-inflammatory agent Substances 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 229940125715 antihistaminic agent Drugs 0.000 abstract 1
- 239000000739 antihistaminic agent Substances 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 210000003630 histaminocyte Anatomy 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 150000002617 leukotrienes Chemical class 0.000 abstract 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000000770 proinflammatory effect Effects 0.000 abstract 1
- 150000003180 prostaglandins Chemical class 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Forma de dosificacion que comprende 10-[(3S)-1-azabiciclo[2.2.2]oct-3-ilmetil]-10H-fenotiazina, provista en forma adecuada para la administracion oral de una dosis diaria de 1 mg a 3 mg. Reivindicacion 8: El uso de 10-[(3S)-1-azabiciclo[2.2.2]oct-3-ilmetil]-10H-fenotiazina, o por lo menos una sal farmacéuticamente aceptable para uso farmacéutico de la misma, en la preparacion de un fármaco que se presenta en una forma de dosificacion adecuada para la administracion oral de una dosis diariade 1 mg a 3 mg para la prevencion y/o tratamiento de trastornos alérgicos, muy especialmente la rinitis alérgica. Reivindicacion 14: El uso de acuerdo con cualquiera de las reivindicaciones 8 a 13, que se caracteriza por el hecho de que dichofármaco se utiliza en combinacion con otro ingrediente activo seleccionado entre antihistamínicos, inhibidores de la lipoxigenasa, antiinflamatorios, inhibidores de la liberacion de citoquinas proinflamatorias, antagonistas del receptor deleucotrienos, o compuestos que controlar la liberacion de mediadores de los mastocitos, como por ejemplo leucotrienos, prostaglandinas, tromboxano A2 o factor activador del de plaquetas.Dosage form comprising 10 - [(3S) -1-azabicyclo [2.2.2] oct-3-ylmethyl] -10H-phenothiazine, provided suitably for oral administration of a daily dose of 1 mg to 3 mg. Claim 8: The use of 10 - [(3S) -1-azabicyclo [2.2.2] oct-3-ylmethyl] -10H-phenothiazine, or at least one pharmaceutically acceptable salt for pharmaceutical use thereof, in the preparation of a drug that is presented in a dosage form suitable for oral administration of a daily dose of 1 mg to 3 mg for the prevention and / or treatment of allergic disorders, most especially allergic rhinitis. Claim 14: The use according to any of claims 8 to 13, characterized in that dichopharmaceutical is used in combination with another active ingredient selected from antihistamines, lipoxygenase inhibitors, anti-inflammatories, cytokine release inhibitors proinflammatory, deleukotriene receptor antagonists, or compounds that control the release of mast cell mediators, such as leukotrienes, prostaglandins, thromboxane A2 or platelet activating factor.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0755075A FR2916142A1 (en) | 2007-05-15 | 2007-05-15 | PHARMACEUTICAL FORM COMPRISING (10 - [(3S) -1-AZABICYCLO [2.2.2] OCT-3-YLMETHYL] -10H-PHENOTHIAZINE PRESENTING IN AN APPROPRIATE FORM FOR ADMINISTRATION OF A DAILY DOSE UNDER BETWEEN 1 AND 3 MG |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR066587A1 true AR066587A1 (en) | 2009-09-02 |
Family
ID=38752476
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080102067A AR066587A1 (en) | 2007-05-15 | 2008-05-15 | DOSAGE FORM INCLUDING 10 - [(3S)) - 1-AZABICICLO [2.2.2] OCT-3 -ILMETIL] -10H-PHENOTIAZINE PROVIDED IN ADEQUATE FORM FOR ORAL ADMINISTRATION OF A DAILY DOSE OF 1 MG TO 3 MG |
Country Status (4)
| Country | Link |
|---|---|
| AR (1) | AR066587A1 (en) |
| FR (1) | FR2916142A1 (en) |
| TW (1) | TW200906417A (en) |
| WO (1) | WO2008138968A2 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021503499A (en) * | 2017-11-17 | 2021-02-12 | ニューラナ ファーマスーティカルズ, インコーポレイテッドNeurana Pharmaceuticals, Inc. | How to administer tolperisone |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2522660A1 (en) * | 1982-03-05 | 1983-09-09 | Pharmuka Lab | MEQUITAZINE LEVOGYER ISOMER, PROCESS FOR PREPARING THE SAME AND MEDICAMENTS CONTAINING THE SAME |
| JPH07188040A (en) * | 1993-12-27 | 1995-07-25 | Taisho Pharmaceut Co Ltd | Composition for treating rhinitis |
| FR2772029B1 (en) * | 1997-12-08 | 2000-02-25 | Pf Medicament | PROCESS FOR THE PREPARATION OF MEQUITAZINE AND NOVEL SYNTHESIS INTERMEDIATE |
| JP2000191536A (en) * | 1998-10-20 | 2000-07-11 | Taisho Pharmaceut Co Ltd | Oral solid preparation containing mequitazine |
| WO2005037245A2 (en) * | 2003-10-21 | 2005-04-28 | Direct-Haler A/S | A multiple route medication for the treatment of rhinitis and asthma |
| JP2006096749A (en) * | 2004-08-31 | 2006-04-13 | Takeda Chem Ind Ltd | Medicine composition for common cold |
| FR2896690B1 (en) * | 2006-01-30 | 2008-05-02 | Pierre Fabre Medicament Sa | USE OF MEQUITAZINE ENANTIOMER (S) FOR THE PREPARATION OF A MEDICINAL PRODUCT WHILE LIMITING GENOMIC TOXICITY |
-
2007
- 2007-05-15 FR FR0755075A patent/FR2916142A1/en not_active Withdrawn
-
2008
- 2008-05-13 TW TW097117537A patent/TW200906417A/en unknown
- 2008-05-15 AR ARP080102067A patent/AR066587A1/en unknown
- 2008-05-15 WO PCT/EP2008/055971 patent/WO2008138968A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008138968A3 (en) | 2009-05-22 |
| WO2008138968A2 (en) | 2008-11-20 |
| TW200906417A (en) | 2009-02-16 |
| WO2008138968A4 (en) | 2009-07-02 |
| FR2916142A1 (en) | 2008-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2553742T3 (en) | Pharmaceutical dosage form comprising 6'-fluor- (N-methyl- or N, N-dimethyl) -4-phenyl-4 ', 9'-dihydro-3'H-spiro [cyclohexane-1,1'-pyran [3,4, b] indole] -4-amine | |
| AR048431A1 (en) | GALENIC FORMULATIONS OF ORGANIC COMPOUNDS | |
| AR048705A1 (en) | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF SEXUAL DISORDERS II | |
| AR082803A1 (en) | METHODS AND FORMULATIONS FOR THE TREATMENT OF THROMBOSIS WITH BETRIXABAN AND A GLICOPROTEIN P INHIBITOR | |
| AR061771A1 (en) | THERAPEUTIC ADMINISTRATION SYSTEM | |
| ECSP055733A (en) | AVAILABLE DEFERACIROX TABLETS | |
| AR062167A1 (en) | GASTRORRETENTIVE ADMINISTRATION SYSTEM | |
| GT200100211AA (en) | COMPOSITES OF IMIDAZOL CONDENSED WITH ARILO OR HETEROARILO AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS. (PATENTEFRACTIONARY NO. 1 OF THE INVENTION PATENT APPLICATION NO. PI-2001-0211. | |
| NZ605888A (en) | Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine for the treatment of nociceptive pain | |
| AR040248A1 (en) | PHARMACO FOR THE TREATMENT OF HYPERACTIVE BLADDER | |
| CR9662A (en) | ACTIVE CANABINOID PHARMACEUTICAL INGREDIENT FOR IMPROVED DOSE FORMS | |
| CO6160321A2 (en) | USE OF 2-6- (3-AMINO-PIPERIDIN-1-IL) -3-METIL-2,4-DIOXO-3,4-DIHIDRO-2H-PYRIMIDIN-1-ILMETIL-4-FLUORO-BENZONITRILE | |
| JP2010222367A5 (en) | ||
| AR077284A1 (en) | SOLID PHARMACEUTICAL FIXED DOSAGE COMPOSITIONS INCLUDING IRBESARTAN AND AMLODIPINE, ITS PREPARATION AND THERAPEUTIC APPLICATION | |
| PE20250018A1 (en) | PHARMACEUTICAL DOSAGE FORMS COMPRISING (4S)-24-CHLORINE-4-ETHYL-73-FLUORO-35- METHOXY-32,5-DIOXO-14-(TRIFLUOROMETHYL)-32H-6-AZA-3(4,1)-PYRIDINE-1(1)-[1,2,3]TRIAZOLE- 2(1,2),7(1)-DIBENZENEHEPTAPHANO-74-CARBOXAMIDE | |
| ECSP044986A (en) | PHARMACEUTICAL COMPOSITION INCLUDING LUMIRACOXIB | |
| AR068820A1 (en) | PHARMACEUTICAL COMPOSITION UNDERSTANDING THE COMBINATION OF VENOTONIC AGENTS AND VASOPROTECTORS FOR THE TREATMENT OF CHRONIC VENOUS INSUFFICIENCY AND USE | |
| PE20040973A1 (en) | COMPOSITIONS OF ANTI-HISTAMINES, DECONGESTIVES AND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS | |
| AR046036A1 (en) | RISEDRONATE COMPOSITIONS AND METHODS FOR USE | |
| UY30847A1 (en) | USE OF DIANHYDROHEXITE MONONITRATE DERIVATIVES AS AGENTS FOR THE TREATMENT OF INTESTINAL DISORDERS | |
| AR061233A1 (en) | FORMULATION OF PROLONGED LIBERATION OF NALTREXONA | |
| AR028525A1 (en) | TRANSDERMAL THERAPEUTIC SYSTEM FOR THE ADMINISTRATION OF LERISETRON | |
| AR046146A1 (en) | TRANSDERMAL PHARMACEUTICAL FORMULATIONS FOR SPRAYING THAT INCLUDE AN ACTIVE AGENT, A VP / VA COPOLYMER AND A NON-WATER VEHICLE | |
| AR075866A1 (en) | A DOSE OF AVE5026 FOR THE TREATMENT OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH SEVERE RENAL DETERIORATION. USE. PHARMACEUTICAL COMPOSITION | |
| AR066587A1 (en) | DOSAGE FORM INCLUDING 10 - [(3S)) - 1-AZABICICLO [2.2.2] OCT-3 -ILMETIL] -10H-PHENOTIAZINE PROVIDED IN ADEQUATE FORM FOR ORAL ADMINISTRATION OF A DAILY DOSE OF 1 MG TO 3 MG |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |